Global biotechnology company Shire has appointed Thomas Dittrich as its new Chief Financial Officer and Member of the Board of Directors, as well as a member of the Executive Committee. The move sees Dittrich replace Jeff Poulton, who is set to move to Indigo Ag Inc.
With a background in mechanical engineering and accounting, gaining a number of leadership roles, Dittrich’s experience with Amgen and Sulzer makes him an ideal fit for the healthcare company.
Dr. Flemming Ornskov, MD, MPH, Chief Executive Officer at Shire explained: “Thomas’ wealth of experience while leading the finance teams at numerous multinational companies, including Amgen for several years, will be a tremendous asset for Shire.
“His unique financial skillset and results-oriented mentality make him the right person to lead Shire’s finance function.”
Shire has cemented its presence in over 100 countries, and will see Dittrich take the business to the next level and build on its strong financial growth.
At Sulzer, Dittrich has been instrumental in designing the company’s transformation program and drove key upgrades to finance and IT functions, as well as to capital structure and resource allocation initiatives.
“Thomas is a talented global executive who will bring to Shire a broad range of experiences from both inside and outside the pharmaceutical industry,” said Susan Kilsby, Chairman of the Board at Shire.
“The Board and I look forward to working with him during this transformational time in the Company’s history.”